Evidence map›Paper›PMID 30385851›Full record

ArticleScientific reports2018

Observations on spontaneous tumor formation in mice overexpressing mitotic kinesin Kif14.

Kamakshi Sishtla, Natalie Pitt, Mehdi Shadmand, Michael N O'Hare, Rania S Sulaiman, Anthony L Sinn, Keith Condon, Karen E Pollok, George E Sandusky, Timothy W Corson

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Dysregulation of KIF14 regulates the cell cycle and predicts poor prognosis in cervical cancer: a study based on integrated approaches.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Article
  7. SilencingAging · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Kamakshi SishtlaEugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Natalie PittDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Mehdi ShadmandEugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Michael N O'HareEugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Rania S SulaimanEugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Anthony L SinnMelvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA.
Keith CondonDepartment of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Karen E PollokDepartment of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.
George E SanduskyDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Timothy W CorsonEugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA. tcorson@iu.edu.ORCID http://orcid.org/0000-0002-1402-7875
Indiana University Health · USHypertension Institute · USIndiana University School of MedicineCairo University · EGUniversity of Ulster · GB

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Sara K Quinney · 1999 to 2026
$59.3M
Indiana Clinical and Translational Sciences InstituteKL2TR001106 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$3.2M
Indiana Clinical and Translational Sciences InstituteTL1TR001107 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$2.0M
NCATS NIH HHS KL2 TR001106NCATS NIH HHS TL1 TR001107NCI NIH HHS P30 CA082709
6 · The paper itself

Abstract

The KIF14 locus is gained and overexpressed in various malignancies, with prognostic relevance. Its protein product, a mitotic kinesin, accelerates growth of normal mammary epithelial cells in vitro and retinoblastoma tumours in a mouse model, while KIF14 knockdown blocks growth of brain, liver, ovarian, breast, prostate, and other tumour cells and xenografts. However, the tumour-initiating effects of Kif14 overexpression have not been studied. We aged a cohort of Kif14-overexpressing transgenic mice and wild-type littermates and documented survival, cause of death, and tumour burden. The Kif14 transgene was expressed in all tissues examined, and was associated with increased proliferation marker expression. Neither mouse weights nor overall survival differed between genotypes. However, Kif14 transgenic mice showed a higher incidence of fatal lymphomas (73 vs. 50%, p = 0.03, Fisher's exact test), primarily follicular and diffuse B-cell lymphomas. Non-tumour findings included a bilateral ballooning degeneration of lens in 12% of Kif14 transgenic mice but no wild-type mice (p = 0.02). Overall, this work reveals a novel association of Kif14 overexpression with lymphoma but suggests that Kif14 does not have as prominent a role in initiating cancer in other cell types as it does in accelerating tumour development in response to other oncogenic insults.

Indexed as

AnimalsBiomarkers, TumorCarcinogenesisGene Expression Regulation, NeoplasticGenotypeHumansKinesinsLymphoma, B-CellLymphoma, FollicularMicePrognosisTumor BurdenBiomarkers, TumorKif14 protein, mouseKinesins

Identifiers

PMID30385851
PMCPMC6212535
OpenAlexW2898335696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.